These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 30426904)

  • 1. Design, Synthesis and Evaluation of Novel 3/4-((Substituted benzamidophenoxy) methyl)-N-hydroxybenzamides/propenamides as Histone Deacetylase Inhibitors and Antitumor Agents.
    Anh DT; Thuan NT; Hai PT; Huong LT; Yen NTK; Han BW; Park EJ; Choi YJ; Kang JS; Hue VTM; Han SB; Nam NH
    Anticancer Agents Med Chem; 2019; 19(4):546-556. PubMed ID: 30426904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis and Biological Evaluation of Novel N-hydroxyheptanamides Incorporating 6-hydroxy-2-methylquinazolin-4(3H)-ones as Histone Deacetylase Inhibitors and Cytotoxic Agents.
    Minh NV; Thanh NT; Lien HT; Anh DTP; Cuong HD; Nam NH; Hai PT; Minh-Ngoc L; Le-Thi-Thu H; Chinh LV; Vu TK
    Anticancer Agents Med Chem; 2019; 19(12):1543-1557. PubMed ID: 31267876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of novel N-hydroxybenzamides/N-hydroxypropenamides incorporating quinazolin-4(3H)-ones as histone deacetylase inhibitors and antitumor agents.
    Hieu DT; Anh DT; Tuan NM; Hai PT; Huong LT; Kim J; Kang JS; Vu TK; Dung PTP; Han SB; Nam NH; Hoa ND
    Bioorg Chem; 2018 Feb; 76():258-267. PubMed ID: 29223029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
    Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation.
    Vu TK; Thanh NT; Minh NV; Linh NH; Thao NTP; Nguyen TTB; Hien DT; Chinh LV; Duc TH; Anh LD; Hai PT
    Med Chem; 2021; 17(7):732-749. PubMed ID: 32310052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
    Huong TT; Dung DT; Huan NV; Cuong LV; Hai PT; Huong LT; Kim J; Kim YG; Han SB; Nam NH
    Bioorg Chem; 2017 Apr; 71():160-169. PubMed ID: 28196602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Huong LT; Park EJ; Choi JE; Kang JS; Dung PTP; Han SB; Nam NH
    Chem Biodivers; 2018 Jun; 15(6):e1800027. PubMed ID: 29667768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 3-substituted-2-oxoindoline-based N-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents.
    Dung do TM; Dung PT; Oanh DT; Hai PT; Huong le TT; Loi VD; Hahn H; Han BW; Kim J; Han SB; Nam NH
    Med Chem; 2015; 11(8):725-35. PubMed ID: 26133355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploration of certain 1,3-oxazole- and 1,3-thiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Anh DT; Hai PT; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Dung DTM; Anh VT; Hue VTM; Han SB; Nam NH
    Bioorg Chem; 2020 Aug; 101():103988. PubMed ID: 32534346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT; Anh DT; Hai PT; Thuan NT; Huong LT; Park EJ; Young Ji A; Soon Kang J; Phuong Dung PT; Han SB; Nam NH
    Chem Biodivers; 2019 Apr; 16(4):e1800502. PubMed ID: 30653817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Hydroxamic Acids Incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis.
    Dung DTM; Huan NV; Cam DM; Hieu DC; Hai PT; Huong LT; Kim J; Choi JE; Kang JS; Han SB; Nam NH
    Med Chem; 2018; 14(8):831-850. PubMed ID: 29807520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel (E)-3-(3-Oxo-4-substituted-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxypropenamides as Histone Deacetylase Inhibitors: Design, Synthesis and Bioevaluation.
    Minh Sang D; Ho Na I; Tien Anh D; Thi Mai Dung D; Thi Thu Hang N; Phuong-Anh NT; Hai PT; Thi Kim Oanh D; Thanh Tung T; Jung Lee S; Hee Kwon J; Soon Kang J; Han SB; Thi Thanh Hai D; Nam NH
    Chem Biodivers; 2023 May; 20(5):e202201030. PubMed ID: 37017259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
    Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
    Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
    Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
    Chen C; Hou X; Wang G; Pan W; Yang X; Zhang Y; Fang H
    Eur J Med Chem; 2017 Jun; 133():11-23. PubMed ID: 28371677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
    Kim DK; Lee JY; Kim JS; Ryu JH; Choi JY; Lee JW; Im GJ; Kim TK; Seo JW; Park HJ; Yoo J; Park JH; Kim TY; Bang YJ
    J Med Chem; 2003 Dec; 46(26):5745-51. PubMed ID: 14667227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
    Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
    Nam NH; Huong TL; Dung do TM; Dung PT; Oanh DT; Quyen D; Thao le T; Park SH; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB
    Eur J Med Chem; 2013; 70():477-86. PubMed ID: 24185378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
    Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
    Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.